by Richard Daverman, PhD
May 17,, 2012 -- Johnson & Johnson is actively pursuing M&A in China as a way of keeping its revenue growth at least equal to the general rise in China’s pharmaceutical market – which J&J estimates to be 17%. J&J is especially interested in companies that would add products to its portfolio of mental health drugs and cancer treatments. Unlike some of its big pharma competitors, the company is not branching out into generic drugs as a way to increase China revenues. More details....
